We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.82 | -1.79% | 44.88 | 45.20 | 44.82 | 45.12 | 3,506,663 | 21:43:35 |
From May 2019 to May 2024
LONDON--GlaxoSmithKline PLC (GSK.LN) has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration for its influenza vaccine Flulaval Quadrivalent.
The healthcare company said Tuesday that the vaccine is currently approved for active immunisation against influenza A subtype viruses and type B viruses, in persons three years of age and older.
The submission seeks an expanded indication for children six months through 35 months of age, it said.
GlaxoSmithKline shares at 1410 GMT down 8 pence, or 0.5%, at GBP14.27, valuing the company at GBP69.54 billion.
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
(END) Dow Jones Newswires
February 02, 2016 09:29 ET (14:29 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
